Find the latest science, technology and partners in antibody engineering, immunobiology and next generation binders.

Strategies to Innovate the Production of Next Generation Bioconjugates

Share this article

From ADC development to tumor-targeting, there are still many lessons to be learned in the world of conjugation.

This whitepaper reviews the latest common challenges and novel strategies for accelerating bioconjugates, across preclinical, research & development and CMC considerations.

It includes:

  • Antibody, site, linker & payload combinations to optimize ADCs
  • Improved targeting for solid tumors
  • Novel payloads and delivery vehicles including antibody fragment–drug, centyrin, peptide drug and oligonucleotide conjugates

Click on the image below or here to explore the whitepaper. 

 

Have any questions about the report or interested in sponsoring a future whitepaper? Email andrew.burrows@informa.com.

Share this article

Subscribe to our monthly Antibody Engineering newsletter

Upcoming event

Antibody Engineering & Therapeutics US

13 - 17 Dec 2021, San Diego, CA
THE #1 ANTIBODY ENGINEERING CONFERENCE FOR ACCELERATING NEXT GENERATION ANTIBODIES TO COMMERCIAL SUCCESS
Go to site